Harrow Health's Growth Trajectory: A Buy Rating Amid Strong Product Performance and Strategic Market InvestmentsTipRanks Financial Blog • about 1 month ago
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Harrow Health (HROW Research Report) today and set a price target of $26.00...
Share to Feed
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Company also posted its fourth quarter and...
Harrow Health, Inc. (NASDAQ:HROW Get Free Report) was the target of a significant increase in short interest in February. As of February 29th, there was short interest totalling 5,490,000...
Kennedy Capital Management LLC purchased a new stake in Harrow Health, Inc. (NASDAQ:HROW Free Report) during the third quarter, HoldingsChannel reports. The institutional investor purchased...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2023, on...
Harrow, Inc. (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Apotex Inc. (Apotex), Canadas largest pharmaceutical company, today jointly announced an exclusive out-licensing...
Allspring Global Investments Holdings LLC purchased a new position in Harrow Health, Inc. (NASDAQ:HROW Free Report) during the 3rd quarter, according to the company in its most recent filing...
In a report released today...